Humanized Antibody Conjugates for MUC1 Epitope Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic modalities for pancreatic cancer, including vaccines targeting mucins and mutated K-ras oncogene polypeptides, have been ineffective due to immune evasion and insufficient tumor site delivery, and there is a need for compositions and methods to detect and treat tumors and cancer stem cells effectively.
Innovation Solution
Development of humanized antibodies and fragments that specifically bind to tumor-associated epitopes of MUC1 and mutated K-ras polypeptides, conjugated with immune modulating agents or diagnostic/detectable labels for targeted therapy and detection of pancreatic and other epithelial tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines target mucins and mutated K-ras oncogene polypeptides, then therapeutic intervention is attempted, but immune response fails due to tumor adaptation and immune evasion
Solution Approach 1:
The patent changes the target parameter from general tumor antigens (mucins, K-ras) to a specific epitope (STAPPVHNV sequence) within MUC1. This parameter change enables more precise immune targeting, overcoming the non-specificity that allows tumor adaptation and immune evasion.
Solution Approach 2:
The patent creates humanized antibodies that copy the binding specificity of murine antibodies against the MUC1 epitope, but with human antibody sequences. This allows the therapy to maintain high affinity binding to the tumor epitope while avoiding immune rejection and enabling long-term persistence in the host.
2Reliability
If immune modulating agents are administered, then immune response is modulated, but delivery is insufficient due to lack of tumor site concentration
Solution Approach 1:
The patent uses the MUC1 epitope as an intermediary target. The humanized antibodies bind specifically to this epitope on tumor cells, serving as a mediator that concentrates the immune modulating effect at the tumor site. This intermediary binding mechanism ensures sufficient local concentration of therapeutic activity.
Solution Approach 2:
The patent achieves local quality by directing the immune response specifically to the tumor site through epitope-specific antibody binding. The therapeutic effect is concentrated where needed (at the tumor) rather than being distributed systemically, improving delivery efficiency and reducing off-target effects.
3Quantity of substance
If antibodies bind to normal cells, then therapeutic coverage is achieved, but unwanted side effects occur
Solution Approach 1:
The patent applies local quality by ensuring the antibody binding is specific to the tumor epitope STAPPVHNV within MUC1, which is differentially expressed on tumor cells but not on normal cells. This specificity creates a local therapeutic effect at the tumor site while avoiding binding to and damage of normal tissues.
Solution Approach 2:
The patent copies the high-specificity binding characteristics of murine anti-MUC1 antibodies into humanized antibody formats. This copying preserves the epitope-specificity that distinguishes tumor cells from normal cells, thereby maintaining therapeutic coverage while eliminating the off-target binding that causes side effects.
4Reliability
If treatment addresses primary disease, then tumor is treated, but metastasis prevention is insufficient
Solution Approach 1:
The patent achieves universality by designing a therapy that targets a conserved epitope (STAPPVHNV) within MUC1 that is present on both primary tumors and metastatic cells. This single epitope target provides multi-functionality: it treats the primary disease while also being capable of detecting and treating metastatic disease, as the epitope is preserved during metastasis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The humanized antibodies provide specific targeting and binding to tumor cells, enhancing immune response and detection capabilities, potentially improving treatment outcomes for pancreatic and other epithelial cancers by specifically targeting cancer cells and preventing metastasis.
Implementation Method 1
humanized antibodies, or fragments or derivatives thereof, which bind to antigens present in tumors
Data Source
AI summary
Provided are antibodies, and fragments, derivatives, and nanoparticle conjugates thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.